Derek DiRocco

Derek DiRocco has worked in the financial industry since 2013, when they began their career at RA Capital Management, L.P. as a Partner, Principal, Analyst, and Associate. In 2018, they became a Director at 89bio. In 2019, they were appointed as a Director at Frontier Medicines and a Board Observer at Peloton Therapeutics. In 2020, they were a Director at iTeos Therapeutics SA and a Board Observer at Vaxcyte. In 2021, they were a Director at Acrivon Therapeutics, Inc. and Werewolf Therapeutics. Finally, in 2022, they became a Director at Mineralys Therapeutics, Inc. and Rivus Pharmaceuticals.

Derek DiRocco obtained a B.A. in Biology from the College of the Holy Cross between 1998 and 2002. Derek then went on to earn a PhD in Pharmacology from the University of Washington - School of Medicine between 2004 and 2009.